Last reviewed · How we verify
Rituximab (EU)
Rituximab is a monoclonal antibody that targets and depletes CD20-positive B cells.
Rituximab is a monoclonal antibody that targets and depletes CD20-positive B cells. Used for Non-Hodgkin's lymphoma, Chronic lymphocytic leukemia.
At a glance
| Generic name | Rituximab (EU) |
|---|---|
| Also known as | MabThera® |
| Sponsor | Amgen |
| Drug class | Monoclonal antibody |
| Target | CD20 |
| Modality | Small molecule |
| Therapeutic area | Oncology, Immunology |
| Phase | Phase 3 |
Mechanism of action
By binding to the CD20 antigen on the surface of B cells, rituximab triggers cell-mediated cytotoxicity and antibody-dependent cellular cytotoxicity, leading to the depletion of B cells. This mechanism is particularly effective in treating B cell malignancies and autoimmune diseases.
Approved indications
- Non-Hodgkin's lymphoma
- Chronic lymphocytic leukemia
Common side effects
- Infusion-related reactions
- Infections
- Neutropenia
- Thrombocytopenia
- Anemia
Key clinical trials
- A Phase III Transition Study of DRL Rituximab to Reference Medicinal Products (PHASE3)
- MabionCD20® Compared to MabThera® and Rituxan® in Patients With Rheumatoid Arthritis (PHASE3)
- PK Similarity Prospective Phase 3 Study in Patients With Rheumatoid Arthritis (PHASE3)
- Evaluate the Efficacy and Safety of HLX01 Versus Mabthera in Patients With Low Tumour Burden Follicular Lymphoma. (PHASE3)
- Study to Assess if ABP 798 is Safe & Effective in Treating Moderate to Severe Rheumatoid Arthritis (RA) Compared to Rituximab (PHASE3)
- A Study of JHL1101 Versus MabThera® in Subjects With Severe Rheumatoid Arthritis (PHASE1)
- A Pharmacokinetic/Pharmacodynamic Study Comparing PF-05280586 To Rituximab In Subjects With Active Rheumatoid Arthritis With An Inadequate Response To TNF Inhibitors (REFLECTIONS B328-01) (PHASE2)
- A Study Of PF-05280586 (Rituximab-Pfizer) Or MabThera® (Rituximab-EU) For The First-Line Treatment Of Patients With CD20-Positive, Low Tumor Burden, Follicular Lymphoma (REFLECTIONS B328-06) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Rituximab (EU) CI brief — competitive landscape report
- Rituximab (EU) updates RSS · CI watch RSS
- Amgen portfolio CI